Entering text into the input field will update the search result below

Premarket analyst action - healthcare

Aug. 17, 2018 7:48 AM ETTravere Therapeutics, Inc. (TVTX) StockLGND, ACER, FOLD, TVTX, ESPR, DARE, LIFEBy: Douglas W. House, SA News Editor
  • Retrophin (NASDAQ:RTRX) initiated with Buy rating and $36 (33% upside) price target at Canaccord Genuity citing future catalysts such as proof-of-concept data on CNSA-001 in PKU in early 2019 and Phase 3 data on fosmetpantotenate in PKAN in H2 2019.
  • Daré Bioscience (NASDAQ:DARE) initiated with Buy rating at Maxim Group.
  • Ligand Pharmaceuticals (NASDAQ:LGND) initiated with Neutral rating and $256 (8% upside) price target at Goldman Sachs.
  • Esperion Therapeutics (NASDAQ:ESPR) upgraded to Buy at Citigroup. Shares up 3% premarket.
  • Acer Therapeutics (NASDAQ:ACER) upgraded to Strong Buy with a $46 (77% upside) price target at Raymond James. Shares up 10% premarket.
  • ATyr Pharma (NASDAQ:LIFE) upgraded to Neutral at Citigroup.
  • Amicus Therapeutics (NASDAQ:FOLD) downgraded to Neutral with a $15 (11% upside) price target at Chardan Capital Markets citing diminished prospects for Galafold over the next six months. Shares down 3% premarket.

Recommended For You

More Trending News

About TVTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TVTX--
Travere Therapeutics, Inc.